Infinity Pharmaceuticals Inc.  

(Public, NASDAQ:INFI)   Watch this stock  
Find more results for INFI
14.35
-0.10 (-0.69%)
Mar 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 14.33 - 14.94
52 week 8.40 - 18.25
Open 14.47
Vol / Avg. 562,971.00/697,932.00
Mkt cap 690.54M
P/E     -
Div/yield     -
EPS -0.36
Shares 48.92M
Beta 1.12
Inst. own 96%
Jun 15, 2015
Infinity Pharmaceuticals, Inc. Annual Shareholder Meeting (Estimated) Add to calendar
May 4, 2015
Q1 2015 Infinity Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Feb 25, 2015
Infinity Pharmaceuticals Inc at RBC Healthcare Conference
Feb 24, 2015
Q4 2014 Infinity Pharmaceuticals Inc Earnings Call - Webcast
Feb 24, 2015
Q4 2014 Infinity Pharmaceuticals Inc Earnings Release
Jan 12, 2015
Infinity Pharmaceuticals Inc at JPMorgan Healthcare Conference - Q&A Session
Jan 12, 2015
Infinity Pharmaceuticals Inc at JPMorgan Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -926.15% -10.56%
Operating margin -897.80% -4.80%
EBITD margin - -3.73%
Return on average assets -42.25% -5.81%
Return on average equity -71.13% -8.48%
Employees 195 -
CDP Score - -

Address

780 Memorial Dr
CAMBRIDGE, MA 02139-4613
United States - Map
+1-617-4531000 (Phone)
+1-617-4531001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Infinity Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to discovering, developing and delivering medicines to people with difficult-to-treat diseases. The Company develops small molecule drugs that target emerging disease pathways. The Company has worldwide development and commercialization rights to all of its development candidates and early discovery programs, subject to certain financial obligations to its current licensor and former development partners. The Company operates in one business segment, which focuses on drug discovery and development. IPI-145, the Company�s lead product candidate, is a potent, oral inhibitor of Class I delta and gamma isoforms of phosphoinositide-3-kinase, or PI3K, which the Company is investigating in both hematologic malignancies and inflammatory diseases. The PI3Ks are a family of enzymes involved in multiple cellular functions, including cell proliferation and survival, cell differentiation, cell migration and immunity.

Officers and directors

Adelene Q. Perkins Chairman of the Board, President, Chief Executive Officer
Age: 54
Bio & Compensation  - Reuters
Lawrence E. Bloch M.D., J.D. Chief Financial Officer, Executive Vice President, Chief Business Officer
Age: 49
Bio & Compensation  - Reuters
Julian Adams Ph.D. President - Research & Development
Age: 59
Bio & Compensation  - Reuters
Vito J. Palombella Ph.D. Chief Scientific Officer
Age: 51
Bio & Compensation  - Reuters
David A. Roth M.D. Chief Medical Officer
Age: 51
Bio & Compensation  - Reuters
Norman C. Selby Lead Outside Independent Director
Age: 62
Bio & Compensation  - Reuters
Jose Baselga M.D., Ph.D. Independent Director
Age: 54
Bio & Compensation  - Reuters
Jeffrey Berkowitz J.D. Independent Director
Age: 48
Bio & Compensation  - Reuters
Anthony B. Evnin Ph.D. Independent Director
Age: 73
Bio & Compensation  - Reuters
Gwendolyn A. Fyfe M.D. Independent Director
Age: 62
Bio & Compensation  - Reuters